CN114524778A - 苯并五元含氮杂环类化合物及其制备方法和用途 - Google Patents
苯并五元含氮杂环类化合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN114524778A CN114524778A CN202210162533.4A CN202210162533A CN114524778A CN 114524778 A CN114524778 A CN 114524778A CN 202210162533 A CN202210162533 A CN 202210162533A CN 114524778 A CN114524778 A CN 114524778A
- Authority
- CN
- China
- Prior art keywords
- substituted
- compound
- unsubstituted
- 300mhz
- esi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 nitrogen-containing heterocyclic compound Chemical class 0.000 title claims abstract description 46
- 125000005605 benzo group Chemical group 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 36
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims abstract description 21
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims abstract description 21
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical group C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims abstract description 17
- 239000003112 inhibitor Substances 0.000 claims abstract description 13
- 230000019491 signal transduction Effects 0.000 claims abstract description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 6
- 125000001424 substituent group Chemical group 0.000 claims description 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 125000000623 heterocyclic group Chemical group 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 6
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 6
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 6
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 125000003368 amide group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000002837 carbocyclic group Chemical group 0.000 claims description 6
- 229910052805 deuterium Inorganic materials 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 230000003287 optical effect Effects 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 238000003786 synthesis reaction Methods 0.000 claims description 5
- OBTZDIRUQWFRFZ-UHFFFAOYSA-N 2-(5-methylfuran-2-yl)-n-(4-methylphenyl)quinoline-4-carboxamide Chemical compound O1C(C)=CC=C1C1=CC(C(=O)NC=2C=CC(C)=CC=2)=C(C=CC=C2)C2=N1 OBTZDIRUQWFRFZ-UHFFFAOYSA-N 0.000 claims description 4
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 230000002924 anti-infective effect Effects 0.000 claims description 3
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 claims description 2
- 238000006069 Suzuki reaction reaction Methods 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 238000009833 condensation Methods 0.000 claims description 2
- 230000005494 condensation Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000006722 reduction reaction Methods 0.000 claims description 2
- 238000006268 reductive amination reaction Methods 0.000 claims description 2
- 238000007363 ring formation reaction Methods 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000118 anti-neoplastic effect Effects 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 6
- 230000000903 blocking effect Effects 0.000 abstract description 4
- 201000011510 cancer Diseases 0.000 abstract description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 150000003384 small molecules Chemical class 0.000 abstract description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 93
- 238000001308 synthesis method Methods 0.000 description 78
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 54
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 238000010189 synthetic method Methods 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 4
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000004576 sand Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 1
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 description 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 description 1
- 102000037978 Immune checkpoint receptors Human genes 0.000 description 1
- 108091008028 Immune checkpoint receptors Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Substances O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229940078552 o-xylene Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 101710135378 pH 6 antigen Proteins 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D263/57—Aryl or substituted aryl radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种能够阻断VISTA信号通路的苯并五元含氮杂环类化合物及其制备方法和用途，该类化合物如下式Ⅰ所示；本发明所述化合物结构新颖，可口服给药，对于阻断VISTA信号通路具有明显的作用，能够有效治疗和缓解癌症等疾病，且作为小分子抑制剂制备简单，方便工业生产。
Description
技术领域
本发明涉及化学医药技术领域，具体涉及阻断VISTA信号通路的苯并五元含氮杂环类化合物及其制备方法和用途。
背景技术
恶性肿瘤是当今世界上最复杂、最难治疗的疾病之一，严重威胁人类健康和生命。肿瘤治疗的方式主要包括手术、放疗、化疗以及靶向治疗等。肿瘤免疫治疗，是指通过刺激机体免疫系统来提高抗肿瘤免疫效应，从而抑制和杀伤肿瘤细胞的一种治疗方法。随着肿瘤学，免疫学以及分子生物学的综合发展和交叉渗透，对肿瘤发病机制的深入研究，免疫治疗已经取得了多方面的成果，为肿瘤治疗带来了新希望。
肿瘤免疫治疗中的免疫检查点抑制剂是目前比较火热的免疫治疗药物。肿瘤细胞通过上调免疫检查点受体的表达，抑制免疫细胞T细胞活性，完成肿瘤细胞的免疫逃逸。免疫检查点抑制剂则是通过抑制免疫检查点通路，解除免疫细胞T细胞的抑制，激活机体对肿瘤细胞的免疫杀伤，实现肿瘤治疗的作用。目前，已发现的免疫检查点有CTLA-4(cytotoxicT lymphocyte-associated antigen-4)，PD-1(Programmed cell death 1)和TIM3(T cellmembrane 3)等(见Drew M.Pardoll,Nature Review Cancer,2012,12,252)。
T细胞激活抑制物免疫球蛋白可变区结构域(VISTA)是一类主要表达于造血细胞组织的免疫检查点。此外，骨髓细胞、神经质细胞和中性粒细胞中也高表达VISTA。与其他免疫检查点在免疫反应激活后诱导表达的特征不同，VISTA在免疫细胞稳态时期就处于稳定表达。多项研究显示VISTA对免疫系统具有抑制作用。因此，抑制VISTA信号通路，可修复机体抗肿瘤免疫活性，以VISTA信号通路为靶点的抑制剂研究也成为一项研究热点。目前为止，市场上仍没有VISTA信号通路的小分子抑制剂上市。因此，研制具有良好抗肿瘤活性的新型VISTA小分子抑制剂具有重大意义。
发明内容
发明目的：针对现有市场没有VISTA抑制剂药物上市的现状，本发明提供了一种VISTA小分子抑制剂化合物及其制备方法和用途。
技术方案：为了实现上述目的，本发明公开了一种如下式I所示的苯并五元含氮杂环类化合物，其药学上可接受的盐、消旋体、旋光异构体或溶剂化合物：
其中，环A和环B独立地为芳环或芳杂环；
X1独立地为C,O,N或S；
R1独立地为氢、氘、卤素、氰基、取代或未取代的羟基、取代或未取代的氨基、取代或未取代的烷基、取代或未取代的烯基、取代或未取代的炔基、取代或未取代的烷氧基，或氨基酸；
R2独立地为氢、氘、卤素、氰基、取代或未取代的羟基、取代或未取代的氨基、取代或未取代的烷基、取代或未取代的烯基、取代或未取代的炔基、取代或未取代的烷氧基、或相邻两个R2与B环的两个原子形成4-7元取代或未取代的碳环或杂环；
R3为氢、氘、卤素、氰基、取代或未取代的烷基、取代或未取代的烯基、取代或未取代的炔基、取代或未取代的烷氧基；
m为1、2或3；
n为1、2或3。
进一步地，每个R1中，所述的取代的烷基或取代的烷氧基的取代基可以是下列基团中的一个或多个：卤素、氰基、羟基、三氟甲基、C1-4烷基、C1-4烷氧基、C1-4羧基、C1-4酯基或C1-4酰胺基；所述的取代的羟基或取代的氨基中的取代基为下列基团中的一个或多个：C1-8烷基、C1-8酰胺基、C1-8酯基、C1-8羧基、C1-8羟基；其中所述C1-8烷基、C1-8酰胺基、C1-8酯基、C1-8羧基、C1-8羟基任选地可被以下一个或多个取代基取代：羟基、羧基、氰基、氨基、环烷基、芳基、杂环基、烯基、炔基；当取代基为多个时，所述的取代基相同或不同。
进一步地，每个R2中，所述的取代的烷基或取代的烷氧基的取代基可以是下列基团中的一个或多个：卤素、氰基、羟基、三氟甲基、C1-4烷基、C1-4烷氧基、C1-4羧基、C1-4酯基或C1-4酰胺基；所述的取代的羟基或取代的氨基中的取代基为下列基团中的一个或多个：C1-8烷基、C1-8酰胺基、C1-8酯基、C1-8羧基、C1-8羟基；其中所述C1-8烷基、C1-8酰胺基、C1-8酯基、C1-8羧基、C1-8羟基任选地可被以下一个或多个取代基取代：羟基、羧基、氰基、氨基、环烷基、芳基、杂环基、烯基、炔基；当相邻的两个R2和与它们相连的B环上的两个原子共同形成4-7元的取代的碳环或取代的杂环时，所述的取代的碳环或取代的杂环的取代基为下列基团中的一个或多个：卤素、氰基、羟基、三氟甲基、C1-4烷基、C1-4烷氧基、C1-4羧基、C1-4酯基或C1-4酰胺基；当取代基为多个时，所述的取代基相同或不同。
优选的，所述的如式I所示结构的苯并五元含氮杂环化合物，为如下任一种：
进一步地，该化合物还包括其药学上可接受的盐、消旋体、旋光异构体或溶剂化合物。
上述的苯并五元含氮杂环类化合物的制备方法，当X为O,N,S时，所述化合物的合成路线如下所示：
其中，A,B,R1,R2,R3,m,n与所述式I中的定义一致，合成步骤如下：
(1)化合物II与化合物III经缩合关环反应得到化合物IV；
(2)化合物IV与化合物V经Suzuki偶联反应得到化合物VI；
(3)化合物VI经还原反应得到化合物VII；
(4)化合物VII经氧化反应得到化合物VIII；
(5)化合物VIII经还原胺化反应得到化合物IX。
一种药物组合物，其含有治疗有效量的一种或多种具有通式I所述结构的苯并五元含氮杂环类化合物或其药学上可接受的盐、消旋体、旋光异构体或溶剂化合物作为活性成分和药学上可接受的载体。
所述药物组合物是胶囊剂、散剂、片剂、颗粒剂、丸剂、注射剂、糖浆剂、口服液、吸入剂、软膏剂、栓剂或贴剂。
如式I所述结构的苯并五元含氮杂环类化合物在制备作为免疫检查点抑制剂、具有VISTA信号通路抑制活性的抑制剂、抗肿瘤药物、抗感染药物中的用途。
所述药物组合物在制备作为免疫检查点抑制剂、具有VISTA信号通路抑制活性的抑制剂、抗肿瘤药物、抗感染药物中的用途。
有益效果：本发明的苯并五元含氮杂环类化合物结构新颖，可口服给药，对于阻断VISTA信号通路具有明显的作用，能够有效治疗和缓解癌症等疾病，且作为小分子抑制剂制备简单，方便工业生产。
具体实施方式
以下结合实施例对本发明作进一步说明。
实施例1
合成路线：
化合物2的合成
将原料1(5g,26.59mmol)和3-甲醛苯甲酸甲酯(4.8g,29.25mmol)用邻二甲苯(40mL)溶解，加入8g活性炭，通氧气，置油浴140℃回流反应6h。TLC监测，原料反应完全，将反应液用硅藻土抽滤，浓缩滤液，用二氯甲烷溶解，浓缩制砂，经柱层析(石油醚：乙酸乙酯＝60：1)纯化，得化合物2(4g,45％)。
化合物3的合成
将化合物2(1g,3.01mmol)，对氟苯硼酸(463mg,3.31mmol)，四三苯基膦钯(104mg,0.09mmol)，碳酸钾(624mg,4.52mmol)用1,4-二氧六环(10mL)和水(10mL)溶解，充氮气球保护，于油浴80℃条件下搅拌12h。TLC检测，原料反应完全，硅藻土过滤，乙酸乙酯萃取，饱和食盐水洗涤，无水硫酸钠干燥，过滤，滤液浓缩制砂，经柱层析(石油醚：乙酸乙酯＝20：1)纯化，得化合物3(760mg,73％)。
化合物4的合成
将化合物3(500mg,1.44mmol)用四氢呋喃(10mL)溶解，在冰浴条件下，分批加入氢化铝锂(164mg,4.32mmol)，于0℃下反应1h。TLC监测，原料反应完。滴加甲醇淬灭反应，用乙酸乙酯萃取，饱和食盐水洗涤，无水硫酸钠干燥，过滤，滤液浓缩制砂，经柱层析(石油醚：乙酸乙酯＝2：1)纯化，得化合物4(390mg,85％)。
化合物5的合成
将化合物4(145mg,0.454mmol)溶于5mL二氯甲烷中，冰浴条件下加入戴斯马丁试剂(76mg,0.908mmol)，后移至室温反应1h，TLC监测反应完毕，加入饱和硫代硫酸钠溶液和饱和碳酸氢钠溶液淬灭，二氯甲烷萃取，饱和食盐水洗涤，无水硫酸钠干燥，过滤，化合物JC-1的合成
将化合物6(60mg)和乙醇胺(24mg)用甲醇(2mL)和二氯甲烷(2mL)溶解，加入1滴冰醋酸，室温搅拌1h，然后加入氰基硼氢化钠(60mg)，继续室温搅拌12h，TLC监测反应完毕，加入饱和碳酸氢钠溶液洗涤，二氯甲烷萃取，无水硫酸钠干燥，过滤，滤液浓缩制砂，经柱层析(二氯甲烷：甲醇＝20：1)得化合物JC-1(58mg,85％)1H NMR(300MHz,Chloroform-d)δ8.30–8.11(m,2H),7.87–7.71(m,2H),7.65–7.48(m,5H),7.26–7.11(m,2H),3.95(s,2H),3.73(dd,J＝5.8,4.5Hz,2H),2.89(dd,J＝5.7,4.6Hz,2H).MS(ESI,m/z):363.5[M+H]+.
实施例2
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.16(d,J＝2.0Hz,1H),8.06(dt,J＝7.4,1.7Hz,1H),7.75(d,J＝1.6Hz,1H),7.71–7.60(m,3H),7.58–7.47(m,3H),7.16(t,J＝8.7Hz,2H),3.85(s,2H),3.36(t,J＝6.4Hz,2H),2.75(t,J＝6.4Hz,2H),1.96(s,3H).MS(ESI,m/z):404.6[M+H]+.
实施例3
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.29–8.06(m,1H),7.80–7.72(m,2H),7.67–7.57(m,4H),7.48–7.35(m,2H),7.22–7.17(m,2H),3.96(dt,J＝5.8,1.0Hz,2H),2.80(td,J＝5.6,4.1Hz,2H),2.63(t,J＝5.6Hz,2H),2.45(s,6H).MS(ESI,m/z):390.7[M+H]+.
实施例4
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.28–8.12(m,2H),7.85–7.71(m,2H),7.62–7.49(m,5H),7.26–7.11(m,2H),3.95(s,2H),3.72(dd,J＝5.8,4.5Hz,2H),2.90(dd,J＝5.7,4.6Hz,2H).MS(ESI,m/z):379.9[M+H]+.
实施例5
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.17(d,J＝2.0Hz,1H),8.06(dt,J＝7.4,1.7Hz,1H),7.75(d,J＝1.6Hz,1H),7.71–7.60(m,3H),7.58–7.47(m,3H),7.16(t,J＝8.7Hz,2H),3.85(s,2H),3.36(t,J＝6.4Hz,2H),2.75(t,J＝6.4Hz,2H),1.96(s,3H).MS(ESI,m/z):420.9[M+H]+.
实施例6
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.28–8.05(m,1H),7.78–7.70(m,2H),7.65–7.55(m,4H),7.49–7.35(m,2H),7.21–7.17(m,2H),3.95(dt,J＝5.6,1.0Hz,2H),2.81(td,J＝5.5,4.1Hz,2H),2.64(t,J＝5.5Hz,2H),2.45(s,6H).MS(ESI,m/z):406.7[M+H]+.
实施例7
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.18–8.01(m,2H),7.75–7.68(m,2H),7.58–7.42(m,5H),7.26–7.10(m,2H),3.98(s,2H),3.64(dd,J＝5.0,3.9Hz,2H),2.85(dd,J＝5.9,3.6Hz,2H).MS(ESI,m/z):413.2[M+H]+.
实施例8
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.19(d,J＝2.2Hz,1H),8.03(dt,J＝6.4,1.9Hz,1H),7.79(d,J＝1.4Hz,1H),7.74–7.65(m,3H),7.55–7.42(m,3H),7.26(t,J＝7.5Hz,2H),3.76(s,2H),3.46(t,J＝5.4Hz,2H),2.78(t,J＝6.4Hz,2H),1.94(s,3H).MS(ESI,m/z):454.6[M+H]+.
实施例9
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.15–8.02(m,1H),7.75–7.68(m,2H),7.63–7.51(m,4H),7.43–7.31(m,2H),7.21–7.12(m,2H),3.95(dt,J＝5.5,1.0Hz,2H),2.86(td,J＝4.5,4.1Hz,2H),2.64(t,J＝6.5Hz,2H),2.46(s,6H).MS(ESI,m/z):440.4[M+H]+.
实施例10
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.20–8.05(m,2H),7.92–7.75(m,2H),7.60–7.43(m,5H),7.23–7.05(m,2H),3.97(s,2H),3.74(dd,J＝5.3,4.3Hz,2H),2.86(dd,J＝5.4,4.8Hz,2H).MS(ESI,m/z):370.5[M+H]+.
实施例11
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.13(d,J＝2.0Hz,1H),8.02(dt,J＝7.0,1.5Hz,1H),7.76(d,J＝1.4Hz,1H),7.71–7.60(m,3H),7.58–7.47(m,3H),7.16(t,J＝8.7Hz,2H),3.85(s,2H),3.36(t,J＝6.3Hz,2H),2.75(t,J＝6.0Hz,2H),1.96(s,3H).MS(ESI,m/z):411.7[M+H]+.
实施例12
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.25–8.04(m,2H),7.75–7.68(m,2H),7.61–7.51(m,3H),7.47–7.34(m,2H),7.21–7.18(m,2H),3.94(dt,J＝5.6,1.0Hz,2H),2.82(td,J＝5.5,4.1Hz,2H),2.65(t,J＝5.5Hz,2H),2.46(s,6H).MS(ESI,m/z):397.3[M+H]+.
实施例13
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.21–8.03(m,2H),7.95–7.78(m,2H),7.57–7.41(m,5H),7.21–7.07(m,2H),3.96(s,2H),3.80(s,3H),3.74(dd,J＝5.2,4.3Hz,2H),2.86(dd,J＝5.4,4.6Hz,2H).MS(ESI,m/z):375.5[M+H]+.
实施例14
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.11(d,J＝2.0Hz,1H),8.01(dt,J＝6.9,1.2Hz,1H),7.75(d,J＝1.5Hz,1H),7.70–7.60(m,3H),7.56–7.45(m,3H),7.14(t,J＝8.5Hz,2H),3.85(s,2H),3.78(s,3H),3.35(t,J＝6.2Hz,2H),2.73(t,J＝5.9Hz,2H),1.96(s,3H).MS(ESI,m/z):416.9[M+H]+.
实施例15
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.20–8.01(m,2H),7.71–7.65(m,2H),7.58–7.48(m,3H),7.41–7.32(m,2H),7.20–7.15(m,2H),3.92(dt,J＝5.3,1.0Hz,2H),3.75(s,3H),2.80(td,J＝5.1,4.0Hz,2H),2.66(t,J＝5.2Hz,2H),2.46(s,6H).MS(ESI,m/z):402.5[M+H]+.
实施例16
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.15–8.00(m,1H),7.78–7.71(m,2H),7.69–7.63(m,3H),7.47–7.38(m,4H),4.08(t,J＝7.1Hz,1H),3.93(dt,J＝5.8,1.1Hz,2H),3.84–3.78(m,3H),3.01(td,J＝6.7,4.1Hz,2H).MS(ESI,m/z):381.6[M+H]+.
实施例17
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.20–8.03(m,1H),7.75–7.65(m,2H),7.65–7.58(m,3H),7.42–7.35(m,4H),4.06(t,J＝7.5Hz,1H),3.92(dt,J＝5.3,1.0Hz,2H),3.84–3.80(m,3H),3.03(td,J＝6.2,4.0Hz,2H).MS(ESI,m/z):422.7[M+H]+.
实施例18
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.20–8.07(m,2H),7.75–7.65(m,2H),7.61–7.55(m,2H),7.47–7.37(m,2H),7.26–7.18(m,2H),3.92(dt,J＝5.6,1.0Hz,2H),2.82(td,J＝5.3,4.0Hz,2H),2.65(t,J＝5.2Hz,2H),2.45(s,6H).MS(ESI,m/z):408.2[M+H]+.
实施例19
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.14–8.00(m,1H),7.76–7.70(m,2H),7.68–7.62(m,3H),7.47–7.39(m,4H),4.08(t,J＝7.0Hz,1H),3.93(dt,J＝5.7,1.1Hz,2H),3.85–3.79(m,3H),3.00(td,J＝6.7,4.0Hz,2H).MS(ESI,m/z):397.9[M+H]+.
实施例20
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.21–8.03(m,1H),7.74–7.66(m,2H),7.63–7.57(m,3H),7.42–7.34(m,4H),4.05(t,J＝7.4Hz,1H),3.91(dt,J＝5.3,1.0Hz,2H),3.85–3.80(m,3H),3.03(td,J＝6.2,3.9Hz,2H).MS(ESI,m/z):438.9[M+H]+.
实施例21
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.19–8.07(m,2H),7.77–7.68(m,2H),7.61–7.58(m,2H),7.46–7.37(m,2H),7.26–7.20(m,2H),3.92(dt,J＝5.6,1.0Hz,2H),2.81(td,J＝5.2,4.0Hz,2H),2.66(t,J＝5.1Hz,2H),2.46(s,6H).MS(ESI,m/z):424.6[M+H]+.
实施例22
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.29–8.07(m,2H),7.82–7.62(m,2H),7.61–7.49(m,5H),7.22–7.05(m,2H),3.94(s,2H),3.72(dd,J＝5.7,4.5Hz,2H),2.89(dd,J＝5.7,4.5Hz,2H).MS(ESI,m/z):363.2[M+H]+.
实施例23
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.12(d,J＝1.9Hz,1H),8.02(dt,J＝7.2,1.2Hz,1H),7.71(d,J＝1.9Hz,1H),7.62–7.57(m,3H),7.52–7.49(m,3H),7.11(t,J＝8.4Hz,2H),3.85(s,2H),3.35(t,J＝6.1Hz,2H),2.74(t,J＝6.4Hz,2H),1.95(s,3H).MS(ESI,m/z):404.4[M+H]+.
实施例24
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.23–8.02(m,1H),7.84–7.76(m,2H),7.65–7.52(m,4H),7.47–7.30(m,2H),7.20–7.14(m,2H),3.95(dt,J＝5.8,1.0Hz,2H),2.82(td,J＝5.5,4.1Hz,2H),2.65(t,J＝5.6Hz,2H),2.45(s,6H).MS(ESI,m/z):390.6[M+H]+.
实施例25
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.71–8.61(m,2H),8.26–8.08(m,2H),7.89–7.72(m,2H),7.60(dd,J＝8.2,1.8Hz,1H),7.55–7.43(m,4H),3.92(s,2H),3.74(t,J＝5.1Hz,2H),2.86(t,J＝5.1Hz,2H).MS(ESI,m/z):346.1[M+H]+.
实施例26
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.70–8.62(m,2H),8.22(d,J＝1.9Hz,1H),8.13(dtt,J＝6.2,4.4,2.1Hz,1H),7.81(d,J＝8.3Hz,2H),7.61(dd,J＝8.1,1.8Hz,1H),7.52(ddd,J＝8.7,4.9,1.8Hz,4H),6.61(t,J＝5.5Hz,1H),3.89(s,2H),3.40(q,J＝5.7Hz,2H),2.82(t,J＝5.8Hz,2H),2.01(s,3H).MS(ESI,m/z):387.8[M+H]+.
实施例27
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.72–8.61(m,2H),8.20(d,J＝1.8Hz,1H),8.12(dtt,J＝6.1,4.3,2.1Hz,1H),7.80(d,J＝8.2Hz,2H),7.60(dd,J＝8.0,1.8Hz,1H),7.50(ddd,J＝8.5,4.5,1.9Hz,4H),3.87(s,2H),3.42(q,J＝5.7Hz,2H),2.80(t,J＝5.7Hz,2H),2.44(s,6H).MS(ESI,m/z):373.2[M+H]+.
实施例28
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.68–8.60(m,2H),8.25–8.13(m,2H),7.90–7.75(m,2H),7.61(dd,J＝8.1,2.3Hz,1H),7.59–7.41(m,4H),3.91(s,2H),3.75(t,J＝5.1Hz,2H),2.88(t,J＝5.0Hz,2H).MS(ESI,m/z):346.6[M+H]+.
实施例29
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.74–8.65(m,2H),8.20(d,J＝1.6Hz,1H),8.10(dtt,J＝6.0,4.2,2.6Hz,1H),7.80(d,J＝8.0Hz,2H),7.65(dd,J＝8.1,1.5Hz,1H),7.50(ddd,J＝8.5,4.2,1.5Hz,4H),6.60(t,J＝5.3Hz,1H),3.93(s,2H),3.42(q,J＝5.3Hz,2H),2.80(t,J＝5.8Hz,2H),2.00(s,3H).MS(ESI,m/z):387.7[M+H]+.
实施例30
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.75–8.59(m,2H),8.15(d,J＝2.4Hz,1H),8.10(dtt,J＝5.6,4.0,2.5Hz,1H),7.75(d,J＝8.0Hz,2H),7.64(dd,J＝8.3,1.6Hz,1H),7.48(ddd,J＝8.0,4.2,2.6Hz,4H),3.85(s,2H),3.40(q,J＝5.7Hz,2H),2.86(t,J＝5.2Hz,2H),2.40(s,6H).MS(ESI,m/z):373.3[M+H]+.
实施例31
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.17–8.06(m,1H),7.80–7.65(m,3H),7.54–7.39(m,5H),7.03–6.95(m,2H),4.05(t,J＝6.0Hz,1H),3.95(dt,J＝5.3,1.3Hz,2H),3.86–3.78(m,6H),3.25–3.16(m,4H),3.02(td,J＝4.9,3.5Hz,2H).MS(ESI,m/z):430.5[M+H]+.
实施例32
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.05(d,J＝1.6Hz,1H),7.76(d,J＝8.0Hz,1H),7.61–7.57(m,2H),7.40(m,1H),7.39–7.30(m,4H),6.95–6.80(m,2H),3.91(dt,J＝5.1,1.3Hz,2H),3.75(t,J＝5.7Hz,4H),3.35(td,J＝5.7,4.1Hz,2H),3.25–3.13(m,4H),3.04(td,J＝5.0,4.6Hz,2H),1.96(s,3H).MS(ESI,m/z):471.6[M+H]+.
实施例33
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.08(d,J＝1.5Hz,1H),7.78(d,J＝8.2Hz,1H),7.60–7.55(m,2H),7.43(m,1H),7.38–7.30(m,4H),6.98–6.85(m,2H),3.90(dt,J＝5.4,1.1Hz,2H),3.76(t,J＝5.2Hz,4H),3.37(td,J＝5.7,4.5Hz,2H),3.28–3.13(m,4H),3.04(td,J＝5.4,4.1Hz,2H),2.43(s,6H).MS(ESI,m/z):457.8[M+H]+.
实施例34
合成方法如实施例1。1H NMR(300MHz,Chloroform-d)δ8.25(s,1H),8.17(dt,J＝6.3,2.1Hz,1H),7.85–7.77(m,2H),7.69–7.58(m,3H),7.56–7.44(m,4H),7.43–7.34(m,1H),3.94(s,2H),3.71(t,J＝5.2Hz,2H),2.87(t,J＝5.2Hz,2H).MS(ESI,m/z):345.4[M+H]+.
实施例35
合成方法如实施例1。1H NMR(300MHz,Chloroform-d)δ8.25(d,J＝1.8Hz,1H),8.20–8.13(m,1H),7.84–7.77(m,2H),7.63(ddd,J＝16.3,8.5,1.6Hz,3H),7.53–7.45(m,4H),7.43–7.34(m,1H),6.10(s,1H),3.90(s,2H),3.38(q,J＝5.6Hz,2H),2.82(t,J＝5.8Hz,2H),2.00(s,3H).MS(ESI,m/z):386.5[M+H]+.
实施例36
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.29(s,1H),8.10–8.02(m,3H),7.63–7.52(m,4H),7.49–7.34(m,2H),7.22–7.17(m,2H),3.96(dt,J＝5.98,1.0Hz,2H),2.81(td,J＝5.6,4.1Hz,2H),2.64(t,J＝5.1Hz,2H),2.45(s,6H).MS(ESI,m/z):372.5[M+H]+.
实施例37
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.22–8.08(m,2H),7.64–7.56(m,3H),7.40–7.38(m,2H),7.25–7.10(m,3H),3.97(s,2H),3.75(t,J＝5.4Hz,2H),2.81(t,J＝5.8Hz,2H),2.55(s,3H).MS(ESI,m/z):377.6[M+H]+.
实施例38
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.15–8.09(m,2H),7.57(d,J＝8.0Hz,1H),7.45–7.34(m,4H),7.10(q,J＝8.9,7.5Hz,3H),6.36(s,1H),3.83(s,2H),3.36(q,J＝6.1Hz,2H),2.75(t,J＝6.2Hz,2H),2.56(s,3H),1.99(s,3H).MS(ESI,m/z):418.2[M+H]+.
实施例39
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.20(s,1H),8.15(d,J＝7.5Hz,1H),7.51–7.45(m,1H),7.32(t,J＝7.4Hz,1H),7.30–7.26(m,3H),7.13–7.06(m,3H),4.40(s,1H),3.86(s,2H),2.70(t,J＝5.4Hz,2H),2.52(s,3H),2.45(t,J＝5.8Hz,2H),2.20(s,6H).MS(ESI,m/z):404.6[M+H]+.
实施例40
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.20–8.09(m,2H),7.60–7.54(m,3H),7.43–7.35(m,2H),7.27–7.15(m,3H),3.99(s,2H),3.76(t,J＝5.0Hz,2H),2.80(t,J＝5.9Hz,2H),2.54(s,3H).MS(ESI,m/z):393.7[M+H]+.
实施例41
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.18–8.04(m,2H),7.56(d,J＝7.6Hz,1H),7.45–7.38(m,4H),7.14(q,J＝8.1,7.9Hz,3H),6.35(s,1H),3.81(s,2H),3.35(q,J＝6.1Hz,2H),2.75(t,J＝6.1Hz,2H),2.56(s,3H),2.01(s,3H).MS(ESI,m/z):434.9[M+H]+.
实施例42
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.24(s,1H),8.18(d,J＝7.0Hz,1H),7.50–7.45(m,1H),7.31(t,J＝7.5Hz,1H),7.30–7.27(m,3H),7.13–7.08(m,3H),4.41(s,1H),3.86(s,2H),2.71(t,J＝5.4Hz,2H),2.54(s,3H),2.45(t,J＝5.8Hz,2H),2.20(s,6H).MS(ESI,m/z):420.8[M+H]+.
实施例43
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.20–8.05(m,2H),7.61–7.48(m,3H),7.43–7.34(m,2H),7.23–7.12(m,3H),3.97(s,2H),3.74(t,J＝5.5Hz,2H),2.84(t,J＝5.5Hz,2H),2.54(s,3H).MS(ESI,m/z):376.2[M+H]+.
实施例44
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.18–8.05(m,2H),7.53(d,J＝8.2Hz,1H),7.44–7.28(m,4H),7.12(q,J＝8.5,7.9Hz,3H),6.35(s,1H),3.79(s,2H),3.35(q,J＝6.1Hz,2H),2.72(t,J＝6.2Hz,2H),2.55(s,3H),1.98(s,3H).MS(ESI,m/z):417.8[M+H]+.
实施例45
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.18(s,1H),8.10(d,J＝7.7Hz,1H),7.56–7.48(m,1H),7.38(t,J＝7.6Hz,1H),7.35–7.29(m,3H),7.16–7.07(m,3H),4.42(s,1H),3.84(s,2H),2.72(t,J＝5.8Hz,2H),2.54(s,3H),2.47(t,J＝5.9Hz,2H),2.22(s,6H).MS(ESI,m/z):403.7[M+H]+.
实施例46
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.14–8.00(m,2H),7.49(t,J＝8.3Hz,3H),7.41–7.25(m,4H),7.10(d,J＝8.3Hz,1H),3.91(s,2H),3.73(t,J＝5.5Hz,2H),2.80(t,J＝5.6Hz,2H),2.50(s,3H).MS(ESI,m/z):312.5[M+H]+.
实施例47
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.17–8.05(m,2H),7.54(d,J＝8.3Hz,1H),7.44–7.28(m,6H),7.13(d,J＝8.3Hz,1H),6.40(d,J＝6.1Hz,1H),3.75(s,2H),3.33(q,J＝6.1Hz,2H),2.68(t,J＝6.2Hz,2H),2.55(s,3H).MS(ESI,m/z):433.6[M+H]+.
实施例48
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.16(s,1H),8.05(d,J＝7.3Hz,1H),7.54–7.46(m,1H),7.35(t,J＝7.5Hz,1H),7.35–7.28(m,3H),7.15–7.07(m,3H),4.42(s,1H),3.83(s,2H),2.72(t,J＝5.3Hz,2H),2.54(s,3H),2.47(t,J＝5.3Hz,2H),2.21(s,6H).MS(ESI,m/z):419.8[M+H]+.
实施例49
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.19–8.04(m,2H),7.77(d,J＝8.1Hz,2H),7.70–7.51(m,5H),7.21(d,J＝8.3Hz,1H),3.95(s,2H),3.74(t,J＝5.6Hz,2H),2.82(t,J＝5.6Hz,2H),2.58(s,3H).MS(ESI,m/z):426.5[M+H]+.
实施例50
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.19–8.04(m,2H),7.77(d,J＝8.0Hz,2H),7.69–7.49(m,5H),7.21(d,J＝8.3Hz,1H),3.92(s,2H),3.38(t,J＝6.3Hz,2H),3.33(s,3H),2.79(t,J＝6.4Hz,2H),1.96(s,3H).MS(ESI,m/z):467.8[M+H]+.
实施例51
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.11(s,1H),8.02(d,J＝7.3Hz,1H),7.58–7.49(m,1H),7.35(t,J＝6.9Hz,1H),7.35–7.22(m,3H),7.18–7.07(m,3H),4.46(s,1H),3.81(s,2H),2.75(t,J＝5.1Hz,2H),2.55(s,3H),2.50(t,J＝5.3Hz,2H),2.23(s,6H).MS(ESI,m/z):455.1[M+H]+.
实施例52
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.18–8.03(m,2H),7.81(d,J＝8.2Hz,2H),7.57(dd,J＝8.1,5.5Hz,5H),7.18(d,J＝8.3Hz,1H),3.94(s,2H),3.73(t,J＝5.6Hz,2H),2.81(t,J＝5.6Hz,2H),2.57(s,3H).MS(ESI,m/z):383.7[M+H]+.
实施例53
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.18–8.02(m,2H),7.86–7.77(m,2H),7.63–7.50(m,6H),7.18(d,J＝8.3Hz,1H),3.91(s,2H),3.38(t,J＝6.4Hz,4H),2.78(t,J＝6.4Hz,2H),2.57(s,3H),1.96(s,3H).MS(ESI,m/z):424.2[M+H]+.
实施例54
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.12(s,1H),8.05(d,J＝7.0Hz,1H),7.55–7.49(m,1H),7.31(t,J＝6.9Hz,1H),7.35–7.25(m,3H),7.15–7.02(m,3H),4.45(s,1H),3.84(s,2H),2.79(t,J＝5.1Hz,2H),2.61(s,3H),2.47(t,J＝5.3Hz,2H),2.25(s,6H).MS(ESI,m/z):410.8[M+H]+.
实施例55
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.18–8.02(m,2H),7.62–7.44(m,3H),7.35–7.24(m,2H),7.16(d,J＝8.3Hz,1H),7.06–6.95(m,2H),3.94(s,2H),3.86(s,3H),3.73(t,J＝5.6Hz,2H),2.81(t,J＝5.6Hz,2H),2.55(s,3H).MS(ESI,m/z):388.7[M+H]+.
实施例56
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.18–8.02(m,2H),7.62–7.44(m,3H),7.36–7.24(m,2H),7.16(d,J＝8.3Hz,1H),7.07–6.95(m,2H),3.92(s,2H),3.87(s,3H),3.38(t,J＝6.4Hz,2H),2.79(t,J＝6.4Hz,2H),2.55(s,3H),1.96(s,3H).MS(ESI,m/z):429.3[M+H]+.
实施例57
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.21–8.00(m,2H),7.73–7.65(m,2H),7.56–7.48(m,3H),7.44–7.32(m,2H),7.20–7.16(m,2H),3.92(dt,J＝5.3,1.0Hz,2H),3.76(s,3H),2.80(td,J＝5.1,4.0Hz,2H),2.65(t,J＝5.2Hz,2H),2.45(s,6H).MS(ESI,m/z):415.2[M+H]+.
实施例58
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.19–8.03(m,2H),7.61–7.48(m,3H),7.41–7.25(m,2H),7.18(t,J＝6.6Hz,2H),3.94(s,2H),3.73(t,J＝5.6Hz,2H),2.81(t,J＝5.6Hz,2H),2.56(s,3H).MS(ESI,m/z):394.4[M+H]+.
实施例59
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.14(s,1H),8.07(t,J＝4.2Hz,1H),7.60–7.50(m,3H),7.38–7.24(m,2H),7.21–7.11(m,2H),3.91(s,2H),3.38(t,J＝6.4Hz,2H),2.79(t,J＝6.4Hz,2H),2.56(s,3H),1.96(s,3H).MS(ESI,m/z):435.8[M+H]+.
实施例60
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.21–8.07(m,2H),7.76–7.65(m,2H),7.63–7.55(m,2H),7.45–7.37(m,2H),7.24–7.17(m,2H),3.91(dt,J＝5.6,1.0Hz,2H),2.83(td,J＝5.0,3.5Hz,2H),2.65(t,J＝5.5Hz,2H),2.45(s,6H).MS(ESI,m/z):421.7[M+H]+.
实施例61
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.17–8.01(m,2H),7.61–7.41(m,4H),7.37–7.23(m,2H),7.14(t,J＝5.9Hz,1H),3.93(d,J＝3.1Hz,2H),3.73(t,J＝5.6Hz,2H),2.81(t,J＝5.6Hz,2H),2.54(d,J＝2.8Hz,3H).MS(ESI,m/z):410.2[M+H]+.
实施例62
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.12–7.99(m,2H),7.56–7.40(m,4H),7.31–7.23(m,2H),7.10(d,J＝8.3Hz,1H),3.87(s,2H),3.36(t,J＝6.4Hz,2H),2.76(t,J＝6.4Hz,2H),2.52(s,3H),1.94(s,3H).MS(ESI,m/z):451.8[M+H]+.
实施例63
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.14–8.07(m,2H),7.71–7.65(m,2H),7.56–7.50(m,2H),7.42–7.33(m,2H),7.24–7.14(m,2H),3.91(dt,J＝5.0,1.0Hz,2H),2.73(td,J＝5.2,4.0Hz,2H),2.64(t,J＝5.1Hz,2H),2.57(s,3H),2.46(s,6H).MS(ESI,m/z):437.2[M+H]+.
实施例64
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.25–8.09(m,2H),7.75–7.62(m,2H),7.55–7.43(m,5H),7.20–7.05(m,2H),3.94(s,2H),3.72(dd,J＝5.3,4.9Hz,2H),2.89(dd,J＝5.7,4.5Hz,2H),2.52(s,3H).MS(ESI,m/z):376.8[M+H]+.
实施例65
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.10(d,J＝1.5Hz,1H),8.05(dt,J＝6.5,1.2Hz,1H),7.70(d,J＝1.5Hz,1H),7.60–7.53(m,3H),7.50–7.43(m,3H),7.11(t,J＝8.3Hz,2H),3.82(s,2H),3.36(t,J＝5.4Hz,2H),2.70(t,J＝6.1Hz,2H),2.51(s,3H),1.93(s,3H).MS(ESI,m/z):417.1[M+H]+.
实施例66
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.20–8.05(m,1H),7.80–7.73(m,2H),7.65–7.51(m,4H),7.47–7.28(m,2H),7.23–7.14(m,2H),3.95(dt,J＝5.8,1.0Hz,2H),2.81(td,J＝5.0,4.0Hz,2H),2.65(t,J＝5.1Hz,2H),2.52(s,3H),2.45(s,6H).MS(ESI,m/z):403.2[M+H]+.
实施例67
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.64–8.56(m,2H),8.16(d,J＝1.9Hz,1H),8.09(ddd,J＝5.6,3.6,1.8Hz,1H),7.56(dd,J＝4.7,3.6Hz,3H),7.52–7.45(m,2H),7.21(d,J＝8.3Hz,1H),3.98(s,2H),3.75(t,J＝5.6Hz,2H),2.86(t,J＝5.5Hz,2H),2.60(s,3H).MS(ESI,m/z):359.5[M+H]+.
实施例68
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.63–8.57(m,2H),8.16(s,1H),8.08(dq,J＝7.7,3.2,2.2Hz,1H),7.61–7.53(m,3H),7.52–7.47(m,2H),7.21(d,J＝8.4Hz,1H),3.94(s,2H),3.39(t,J＝6.4Hz,2H),2.81(t,J＝6.4Hz,2H),2.61(s,3H),1.96(s,3H).MS(ESI,m/z):400.3[M+H]+.
实施例69
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.75–8.64(m,2H),8.24(d,J＝1.7Hz,1H),8.15(dtt,J＝6.0,4.6,2.5Hz,1H),7.85(d,J＝8.0Hz,2H),7.64(dd,J＝7.5,1.8Hz,1H),7.56(ddd,J＝8.0,4.1,1.7Hz,4H),3.85(s,2H),3.45(q,J＝5.2Hz,2H),2.81(t,J＝5.7Hz,2H),2.59(s,3H),2.43(s,6H).MS(ESI,m/z):386.7[M+H]+.
实施例70
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.61–8.53(m,2H),8.16(s,1H),8.12–8.05(m,1H),7.91(d,J＝7.8Hz,1H),7.57(dd,J＝8.6,4.3Hz,4H),7.19(d,J＝8.3Hz,1H),3.95(s,2H),3.74(t,J＝5.6Hz,2H),2.83(t,J＝5.6Hz,2H),2.58(s,3H).MS(ESI,m/z):359.8[M+H]+.
实施例71
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.57(d,J＝11.1Hz,2H),8.15(s,1H),8.11–8.04(m,1H),7.89(d,J＝7.3Hz,1H),7.55(t,J＝6.6Hz,4H),7.18(d,J＝7.8Hz,1H),3.92(d,J＝4.8Hz,2H),3.42–3.30(m,3H),2.79(t,J＝6.7Hz,2H),2.58(d,J＝4.0Hz,3H),1.96(s,3H).MS(ESI,m/z):400.9[M+H]+.
实施例72
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.77–8.61(m,2H),8.27(d,J＝1.5Hz,1H),8.15(dtt,J＝5.8,4.3,2.8Hz,1H),7.87(d,J＝7.8Hz,2H),7.62(dd,J＝7.0,1.8Hz,1H),7.56(ddd,J＝8.5,4.2,1.3Hz,4H),3.86(s,2H),3.44(q,J＝5.2Hz,2H),2.82(t,J＝5.7Hz,2H),2.61(s,3H),2.44(s,6H).MS(ESI,m/z):386.4[M+H]+.
实施例73
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.16–8.05(m,1H),7.80–7.65(m,2H),7.52–7.36(m,5H),7.03–6.94(m,2H),3.95(dt,J＝5.4,1.0Hz,2H),3.85–3.76(m,6H),3.26–3.16(m,4H),3.02(td,J＝6.0,4.5Hz,2H),2.43(s,3H).MS(ESI,m/z):443.7[M+H]+.
实施例74
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.05(d,J＝1.6Hz,1H),7.76(d,J＝8.0Hz,1H),7.61–7.57(m,2H),7.40(m,1H),7.39–7.30(m,4H),6.95–6.80(m,2H),3.91(dt,J＝5.1,1.3Hz,2H),3.75(t,J＝5.7Hz,4H),3.35(td,J＝5.7,4.1Hz,2H),3.25–3.13(m,4H),3.04(td,J＝5.0,4.6Hz,2H),2.52(s,3H),1.96(s,3H).MS(ESI,m/z):484.8[M+H]+.
实施例75
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.08(d,J＝1.5Hz,1H),7.78(d,J＝8.2Hz,1H),7.60–7.55(m,2H),7.43(m,1H),7.38–7.30(m,4H),6.98–6.85(m,2H),3.90(dt,J＝5.4,1.1Hz,2H),3.76(t,J＝4.3Hz,4H),3.37(td,J＝6.3,4.5Hz,2H),3.28–3.13(m,4H),3.04(td,J＝5.4,4.1Hz,2H),2.52(s,3H),2.43(s,6H).MS(ESI,m/z):470.2[M+H]+.
实施例76
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.35–8.17(m,2H),7.85–7.74(m,2H),7.68–7.52(m,5H),7.24–7.16(m,2H),3.96(s,2H),3.72(dd,J＝5.1,4.3Hz,2H),2.89(dd,J＝5.4,4.9Hz,2H).MS(ESI,m/z):379.9[M+H]+.
实施例77
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.36–8.18(m,2H),7.89–7.78(m,2H),7.69–7.51(m,5H),7.26–7.18(m,2H),3.95(s,2H),3.75(dd,J＝5.4,4.7Hz,2H),2.89(dd,J＝5.1,4.5Hz,2H),1.96(s,3H).MS(ESI,m/z):420.2[M+H]+.
实施例78
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.30–8.19(m,2H),7.85–7.76(m,2H),7.64–7.55(m,5H),7.24–7.13(m,2H),3.95(s,2H),3.75(dd,J＝5.4,4.7Hz,2H),2.89(dd,J＝5.1,4.5Hz,2H),2.45(s,6H).MS(ESI,m/z):406.5[M+H]+.
实施例79
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.32–8.15(m,2H),7.87–7.76(m,2H),7.66–7.50(m,5H),7.26–7.18(m,2H),3.95(s,2H),3.75(dd,J＝5.0,4.5Hz,2H),2.90(dd,J＝5.0,4.5Hz,2H),2.56(s,3H).MS(ESI,m/z):393.7[M+H]+.
实施例80
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.36–8.18(m,2H),7.89–7.78(m,2H),7.69–7.51(m,5H),7.26–7.18(m,2H),3.95(s,2H),3.75(dd,J＝5.4,4.7Hz,2H),2.89(dd,J＝5.1,4.5Hz,2H),2.55(s,3H),1.95(s,3H).MS(ESI,m/z):434.7[M+H]+.
实施例81
合成方法参照实施例1。1H NMR(300MHz,Chloroform-d)δ8.38–8.15(m,2H),7.85–7.74(m,2H),7.65–7.53(m,5H),7.28–7.19(m,2H),3.96(s,2H),3.75(dd,J＝5.0,4.4Hz,2H),2.90(dd,J＝5.1,4.5Hz,2H),2.54(s,3H),2.44(s,6H).MS(ESI,m/z):420.2[M+H]+.
实施例82
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.24–8.04(m,2H),7.62–7.49(m,3H),7.46–7.37(m,2H),7.21–7.15(m,3H),3.96(s,2H),3.75(t,J＝5.0Hz,2H),2.86(t,J＝5.4Hz,2H).MS(ESI,m/z):380.3[M+H]+.
实施例83
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.22–8.07(m,2H),7.60–7.45(m,3H),7.41–7.34(m,2H),7.20–7.13(m,3H),3.95(s,2H),3.78(t,J＝4.8Hz,2H),2.86(t,J＝5.3Hz,2H).MS(ESI,m/z):440.9[M+H]+.
实施例84
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.20–8.04(m,2H),7.65–7.47(m,3H),7.42–7.30(m,2H),7.23–7.15(m,3H),3.97(s,2H),3.78(t,J＝4.8Hz,2H),2.85(t,J＝5.3Hz,2H).MS(ESI,m/z):430.8[M+H]+.
实施例85
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.22–8.06(m,2H),7.64–7.48(m,3H),7.39–7.26(m,2H),7.21–7.14(m,3H),3.96(s,2H),3.78(t,J＝4.5Hz,2H),2.85(t,J＝5.0Hz,2H).MS(ESI,m/z):387.1[M+H]+.
实施例86
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.15–8.01(m,2H),7.74–7.36(m,5H),7.14–7.08(m,3H),3.99(s,2H),3.84(t,J＝5.6Hz,2H),2.89(t,J＝4.3Hz,2H).MS(ESI,m/z):381.4[M+H]+.
实施例87
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.19–8.05(m,2H),7.79–7.51(m,5H),7.14–7.08(m,3H),3.94(s,2H),3.82(t,J＝5.8Hz,2H),2.83(t,J＝4.0Hz,2H).MS(ESI,m/z):441.8[M+H]+.
实施例88
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.24–8.06(m,2H),7.81–7.47(m,5H),7.11–7.01(m,3H),3.96(s,2H),3.88(t,J＝4.8Hz,2H),2.76(t,J＝3.0Hz,2H).MS(ESI,m/z):431.6[M+H]+.
实施例89
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.20–8.10(m,2H),7.85–7.55(m,5H),7.23–7.08(m,3H),3.94(s,2H),3.80(t,J＝6.0Hz,2H),2.70(t,J＝.0Hz,2H).MS(ESI,m/z):388.8[M+H]+.
实施例90
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.28–8.16(m,2H),7.80–7.44(m,5H),7.12–7.01(m,3H),3.90(s,2H),3.86(t,J＝6.4Hz,2H),2.87(t,J＝3.3Hz,2H).MS(ESI,m/z):397.5[M+H]+.
实施例91
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.27–8.15(m,2H),7.76–7.50(m,5H),7.15–7.05(m,3H),3.88(s,2H),3.81(t,J＝6.4Hz,2H),2.83(t,J＝3.3Hz,2H).MS(ESI,m/z):457.7[M+H]+.
实施例92
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.33–8.25(m,2H),7.86–7.57(m,5H),7.25–7.09(m,3H),4.01(s,2H),3.85(t,J＝5.4Hz,2H),2.88(t,J＝3.9Hz,2H).MS(ESI,m/z):447.6[M+H]+.
实施例93
合成方法参照实施例1。1H NMR(300MHz,Methanol-d4)δ8.30–8.23(m,2H),7.88–7.59(m,5H),7.23–7.12(m,3H),3.99(s,2H),3.83(t,J＝3.5Hz,2H),2.89(t,J＝4.2Hz,2H).MS(ESI,m/z):404.2[M+H]+.
试验例1化合物与VISTA蛋白结合能力实验
(一)实验设备及试剂
1、本实验所用机型：Biacore S200。
2、S系列CM5芯片。货号：29-1049-88(一片装)，BR-1005-30(三片装)，29-1496-03(十片装)，购买地为GE Healthcare。
3、氨基偶联试剂盒。货号：BR-1000-50，购买地为GE Healthcare。
4、缓冲液：10x PBS-P+(货号：28-9950-84)，购买地为GE Healthcare。
5、分析纯DMSO，去离子水(0.22μm膜过滤)。
6、蛋白：糖基化修饰的VISTA蛋白。
7、其他耗材：无盖1.5ml EP管(货号：BR-1002-87)，橡胶瓶盖2型(货号：BR-1004-11)，96孔板(货号：BR-1005-03)，96孔板封口膜(货号：28-9758-16)，购买地为GEHealthcare。
(二)实验步骤
利用Biacore S200系统和CM5芯片测试化合物与VISTA蛋白的结合能力，用1.05*PBS-P稀释10mM化合物母液至10个浓度梯度(5μM,2.5μM,1.25μM,0.625μM,0.3125μM,0.156μM,0.078μM,0.039μM,0.0195μM,0.00975μM),测试得到不同浓度亲和力数据，并拟合得到化合物KD数值。
(三)实验结果
下表为实施例化合物与VISTA蛋白结合的KD数值。
以上对本发明的具体实施例进行了描述，但需要理解的是，本发明并不局限于上述特定的实施方式，本领域技术人员可以在不脱离本发明构思的前提下，做出各种变形和修改，这些都属于本发明的保护范围。
Claims (10)
1.一种如式I所示的苯并五元含氮杂环类化合物，其药学上可接受的盐、消旋体、旋光异构体或溶剂化合物：
其中，环A和环B独立地为芳环或芳杂环；
X1独立地为C,O,N或S；
R1独立地为氢、氘、卤素、氰基、取代或未取代的羟基、取代或未取代的氨基、取代或未取代的烷基、取代或未取代的烯基、取代或未取代的炔基、取代或未取代的烷氧基，或氨基酸；
R2独立地为氢、氘、卤素、氰基、取代或未取代的羟基、取代或未取代的氨基、取代或未取代的烷基、取代或未取代的烯基、取代或未取代的炔基、取代或未取代的烷氧基、或相邻两个R2与B环的两个原子形成4-7元取代或未取代的碳环或杂环；
R3为氢、氘、卤素、氰基、取代或未取代的烷基、取代或未取代的烯基、取代或未取代的炔基、取代或未取代的烷氧基；
m为1、2或3；
n为1、2或3。
2.根据权利要求1所述的苯并五元含氮杂环类化合物，其特征在于，每个R1中，所述的取代的烷基或取代的烷氧基的取代基可以是下列基团中的一个或多个：卤素、氰基、羟基、三氟甲基、C1-4烷基、C1-4烷氧基、C1-4羧基、C1-4酯基或C1-4酰胺基；所述的取代的羟基或取代的氨基中的取代基为下列基团中的一个或多个：C1-8烷基、C1-8酰胺基、C1-8酯基、C1-8羧基、C1-8羟基；其中所述C1-8烷基、C1-8酰胺基、C1-8酯基、C1-8羧基、C1-8羟基任选地可被以下一个或多个取代基取代：羟基、羧基、氰基、氨基、环烷基、芳基、杂环基、烯基、炔基；当取代基为多个时，所述的取代基相同或不同。
3.根据权利要求1所述的苯并五元含氮杂环类化合物，其特征在于，每个R2中，所述的取代的烷基或取代的烷氧基的取代基可以是下列基团中的一个或多个：卤素、氰基、羟基、三氟甲基、C1-4烷基、C1-4烷氧基、C1-4羧基、C1-4酯基或C1-4酰胺基；所述的取代的羟基或取代的氨基中的取代基为下列基团中的一个或多个：C1-8烷基、C1-8酰胺基、C1-8酯基、C1-8羧基、C1-8羟基；其中所述C1-8烷基、C1-8酰胺基、C1-8酯基、C1-8羧基、C1-8羟基任选地可被以下一个或多个取代基取代：羟基、羧基、氰基、氨基、环烷基、芳基、杂环基、烯基、炔基；当相邻的两个R2和与它们相连的B环上的两个原子共同形成4-7元的取代的碳环或取代的杂环时，所述的取代的碳环或取代的杂环的取代基为下列基团中的一个或多个：卤素、氰基、羟基、三氟甲基、C1-4烷基、C1-4烷氧基、C1-4羧基、C1-4酯基或C1-4酰胺基；当取代基为多个时，所述的取代基相同或不同。
4.根据权利要求1-3任一项所述苯并五元含氮杂环类化合物，为如下任一种：
5.根据权利要求1-4任一项所述苯并五元含氮杂环类化合物，其特征在于：该化合物还包括其药学上可接受的盐、消旋体、旋光异构体或溶剂化合物。
6.根据权利要求1-5任一项所述苯并五元含氮杂环类化合物的制备方法，其特征在于，当X为O,N,S时，所述化合物的合成路线如下所示：
其中，A,B,R1,R2,R3,m,n与所述式I中的定义一致，合成步骤如下：
(1)化合物II与化合物III经缩合关环反应得到化合物IV；
(2)化合物IV与化合物V经Suzuki偶联反应得到化合物VI；
(3)化合物VI经还原反应得到化合物VII；
(4)化合物VII经氧化反应得到化合物VIII；
(5)化合物VIII经还原胺化反应得到化合物IX。
7.一种药物组合物，其含有治疗有效量的一种或多种如权利要求1-5任一项所述的苯并五元含氮杂环类化合物或其药学上可接受的盐、消旋体、旋光异构体或溶剂化合物作为活性成分和药学上可接受的载体。
8.根据权利要求7所述的药物组合物，其特征在于，所述药物组合物是胶囊剂、散剂、片剂、颗粒剂、丸剂、注射剂、糖浆剂、口服液、吸入剂、软膏剂、栓剂或贴剂。
9.权利要求1-5任一项所述苯并五元含氮杂环类化合物在制备作为免疫检查点抑制剂、具有VISTA信号通路抑制活性的抑制剂、抗肿瘤药物、抗感染药物中的用途。
10.权利要求7-8任一项所述药物组合物在制备作为免疫检查点抑制剂、具有VISTA信号通路抑制活性的抑制剂、抗肿瘤药物、抗感染药物中的用途。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210162533.4A CN114524778A (zh) | 2022-02-22 | 2022-02-22 | 苯并五元含氮杂环类化合物及其制备方法和用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210162533.4A CN114524778A (zh) | 2022-02-22 | 2022-02-22 | 苯并五元含氮杂环类化合物及其制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114524778A true CN114524778A (zh) | 2022-05-24 |
Family
ID=81624528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210162533.4A Pending CN114524778A (zh) | 2022-02-22 | 2022-02-22 | 苯并五元含氮杂环类化合物及其制备方法和用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114524778A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116903554A (zh) * | 2023-09-13 | 2023-10-20 | 北京科翔中升医药科技有限公司 | Vista和pd-1/pd-l1双靶点小分子抑制剂及其制备方法和用途 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998006703A1 (en) * | 1996-08-14 | 1998-02-19 | Warner-Lambert Company | 2-phenyl benzimidazole derivatives as mcp-1 antagonists |
| CN109081813A (zh) * | 2017-06-14 | 2018-12-25 | 成都海创药业有限公司 | 一类苯并杂环类化合物及其治疗癌症的用途 |
| CN112321513A (zh) * | 2020-11-06 | 2021-02-05 | 中国药科大学 | 杂环类化合物及其制备方法和用途 |
-
2022
- 2022-02-22 CN CN202210162533.4A patent/CN114524778A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998006703A1 (en) * | 1996-08-14 | 1998-02-19 | Warner-Lambert Company | 2-phenyl benzimidazole derivatives as mcp-1 antagonists |
| CN109081813A (zh) * | 2017-06-14 | 2018-12-25 | 成都海创药业有限公司 | 一类苯并杂环类化合物及其治疗癌症的用途 |
| CN112321513A (zh) * | 2020-11-06 | 2021-02-05 | 中国药科大学 | 杂环类化合物及其制备方法和用途 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116903554A (zh) * | 2023-09-13 | 2023-10-20 | 北京科翔中升医药科技有限公司 | Vista和pd-1/pd-l1双靶点小分子抑制剂及其制备方法和用途 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2285693C2 (ru) | Производные пиридина и хинолина, способ их получения, фармацевтическая композиция, применение соединений для лечения заболеваний, ассоциированных с dpp-iv | |
| CA3170068A1 (en) | Spiro ring-containing quinazoline compound | |
| CN106220635B (zh) | 作为parp抑制剂的稠合的四环或五环的二氢二氮杂*并咔唑酮 | |
| CA3068158A1 (en) | .alpha.,.beta.-unsaturated amide compound | |
| CN115175679A (zh) | 治疗雌激素受体相关疾病的方法 | |
| CA2907178A1 (en) | Ido inhibitors | |
| CN102858754A (zh) | Raf抑制剂化合物及其使用方法 | |
| EA020885B1 (ru) | Ингибиторы протеинкиназы и их применение | |
| CN112321513B (zh) | 杂环类化合物及其制备方法和用途 | |
| CN112839944B (zh) | 用于治疗狂犬病的化合物及其方法 | |
| KR20180021820A (ko) | Ido 억제제 | |
| WO2005077920A1 (en) | Quinoxaline compounds and methods of using them | |
| JP2021535909A (ja) | 高活性ｓｔｉｎｇタンパク質アゴニスト化合物 | |
| CN115353508B (zh) | 5-吡啶-1h-吲唑类化合物、药物组合物和应用 | |
| EP3404024A1 (en) | Quinazolinone derivative, preparation method therefor, pharmaceutical composition, and applications | |
| CN114516832A (zh) | 一种微管蛋白抑制剂及其制备方法与应用 | |
| CN114524778A (zh) | 苯并五元含氮杂环类化合物及其制备方法和用途 | |
| Ding et al. | Development of novel phenoxy-diketopiperazine-type plinabulin derivatives as potent antimicrotubule agents based on the co-crystal structure | |
| CA3054459A1 (en) | Azetidine derivative | |
| CN112479988B (zh) | 取代联苯类化合物及其制备方法、用途和药物组合物 | |
| CA3196153A1 (en) | Pyrido[4,3-b]indole derivatives and their use as pharmaceuticals | |
| JP7436630B2 (ja) | アデノシン受容体拮抗薬 | |
| CN116514777A (zh) | 驱动蛋白kif18a抑制剂及其应用 | |
| CN115197167A (zh) | 1,2,4-噻二唑烷-3,5-二酮化合物及其制备方法和应用 | |
| CN107513089B (zh) | 一种新型胞苷衍生物二聚体及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |